Priya Marreddy
Directeur Technique/Scientifique/R&D chez CONTEXT THERAPEUTICS INC.
Postes actifs de Priya Marreddy
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| CONTEXT THERAPEUTICS INC. | Directeur Technique/Scientifique/R&D | 01/04/2022 | - |
Historique de carrière de Priya Marreddy
Anciens postes connus de Priya Marreddy
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Cornerstone Pharmaceuticals, Inc.
 Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Directeur Technique/Scientifique/R&D | - | - |
Formation de Priya Marreddy
| George Washington University | Undergraduate Degree |
| University of Pennsylvania | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 2 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Sectorielle
| Consumer Services | 3 |
| Health Technology | 2 |
| Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CONTEXT THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
- Bourse
- Insiders
- Priya Marreddy
- Expérience
